Denali Therapeutics (NASDAQ:DNLI) Receives Outperform Rating from William Blair

Denali Therapeutics (NASDAQ:DNLI)‘s stock had its “outperform” rating restated by research analysts at William Blair in a research note issued on Wednesday,RTT News reports.

Several other equities analysts also recently weighed in on the stock. Robert W. Baird started coverage on shares of Denali Therapeutics in a report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 target price for the company. Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Jefferies Financial Group upped their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Finally, Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Monday, December 16th. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.91.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $18.74 on Wednesday. The firm has a market capitalization of $2.70 billion, a price-to-earnings ratio of -6.79 and a beta of 1.39. The business’s 50 day simple moving average is $23.64 and its 200-day simple moving average is $24.79. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the firm posted ($0.72) earnings per share. On average, equities analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current year.

Insider Activity

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,020 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now directly owns 111,056 shares of the company’s stock, valued at $3,331,680. This trade represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Alexander O. Schuth sold 15,558 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $29.91, for a total value of $465,339.78. Following the sale, the insider now owns 178,066 shares in the company, valued at approximately $5,325,954.06. The trade was a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 104,518 shares of company stock valued at $2,576,982 in the last three months. Corporate insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in Denali Therapeutics by 6.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock worth $6,857,000 after buying an additional 14,324 shares during the period. Principal Financial Group Inc. grew its stake in shares of Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock valued at $36,076,000 after acquiring an additional 149,939 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Denali Therapeutics by 3.8% during the third quarter. Franklin Resources Inc. now owns 80,041 shares of the company’s stock worth $2,148,000 after acquiring an additional 2,901 shares during the last quarter. Barclays PLC lifted its stake in shares of Denali Therapeutics by 101.4% in the third quarter. Barclays PLC now owns 255,883 shares of the company’s stock worth $7,454,000 after acquiring an additional 128,823 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. purchased a new position in Denali Therapeutics in the third quarter valued at about $1,894,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.